FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743124734> ?p ?o ?g. }

• W2743124734 endingPage "S36" @default.
• W2743124734 startingPage "S35" @default.
• W2743124734 abstract "Thiazide diuretics are often utilized to overcome loop diuretic resistance when treating ADHF. In addition to a large cost advantage, several pharmacokinetic advantages exist when administering oral metolazone (MT) compared to IV chlorothiazide (CT); yet many providers are reluctant to utilize an oral formulation to treat ADHF. Several studies have found no difference in efficacy between the agents, however these studies had limited patients, utilized net UOP which can be misleading if patients are intubated or fluid restricted, and included HFpEF patients which may not have comparable UOP goals to HFrEF patients. The purpose of this study was to compare the increase in 24 hr total UOP after adding MT or CT to IV loop diuretics (LD) in patients with HFrEF. This was an IRB-approved, single-center retrospective chart review. Inclusion criteria were EF ≤40% and >24 hr use of LD with recorded UOP prior to administration of MT ≥ 5 mg or CT ≥ 500 mg. Patients with dialysis, no oral or per tube medications within 24 hr, or an overlap of MT/CT therapy were excluded. Baseline characteristics and safety data were collected in addition to 24 hr UOP prior and post drug administration. A subgroup analysis of patients receiving vasopressors was conducted a priori. From 9/2013-8/2016, 961 patients received either MT or CT in addition to LD. Most patients were excluded for HFpEF (n = 469), < 24 hr LD or UOP data prior to drug initiation (n = 129), or low dose MT/CT (n = 91). A total of 168 patients were included with 64% receiving CT. Baseline characteristics are listed in Table 1. No significant difference was observed between the increase in 24 hr total UOP after MT or CT initiation (1458 (514,2401) mL v. 1820 (890,2750) mL, P = .251). Net UOP and UOP for the entire course of MT or CT therapy are displayed in Figure. Additionally the vasopressor subgroup analysis (MT n = 16, CT n = 34) revealed no difference in increase in UOP between agents (1622 (60,3186) mL v. 1865 (302,3428) mL, P = .506). Both MT and CT similarly increased UOP when utilized as an adjunct to IV loop diuretics. These results may suggest that while thiazide agents can substantially increase UOP in ADHF patients with rEF and diuretic resistance, IV chlorothiazide may not offer benefit beyond oral metolazone 5 mg. A prospective RCT would be necessary to confirm.Table 1Baseline Characteristics for HFrEF Utilizing Thiazides for ADHF with Loop ResistanceBaseline CharacteristicIV Chlorothiazide (n = 108)Oral Metolazone (n = 60)PAge, yr64 (54,69)63 (54,74).558Male Sex, n(%)74 (69)41 (68).98White Race, n(%)68 (63)34 (57).621EF, %22 (15,30)23 (17,30).293BNP, pg/mL1371 (830,2230)1517 (825,3313).620SCr, mg/dL1.5 (1.0,2.1)1.6 (1.2,2.1).328cCrCl, mL/min47 (30,68)43 (30,61).390Total UOP, mL1693 (863,2388)1675 (1113,2591).330Net UOP, mL-350 (±1217)-552 (±1205).303Hospital LOS, days16 (9,28)13 (8,32).502Loop Continuous Infusion, n(%)67 (62)25 (42).011IV Inotropes, n(%)53 (49)24 (40).258ICU, n(%)77 (71)38 (63).287ICU LOS, days4 (0,10)2 (0,8).088Vasopressor, n(%)34 (32)16 (27).892Mechanical Ventilation, n(%)15 (14)2 (3).033APACHE II, score12 (9,15)10 (7,14).099Inhospital Morality, n(%)21 (19)1 (2).001 Open table in a new tab" @default.
• W2743124734 created "2017-08-17" @default.
• W2743124734 creator A5047612641 @default.
• W2743124734 creator A5051913748 @default.
• W2743124734 creator A5063331477 @default.
• W2743124734 creator A5046779846 @default.
• W2743124734 date "2017-08-01" @default.
• W2743124734 modified "2023-09-26" @default.
• W2743124734 title "Oral Metolazone Increases Urine Output Comparable to Chlorothiazide IV as an Adjunct to Loop Diuretics in HFrEF Patients with ADHF" @default.
• W2743124734 doi "https://doi.org/10.1016/j.cardfail.2017.07.095" @default.
• W2743124734 hasPublicationYear "2017" @default.
• W2743124734 type Work @default.
• W2743124734 sameAs 2743124734 @default.
• W2743124734 citedByCount "0" @default.
• W2743124734 crossrefType "journal-article" @default.
• W2743124734 hasAuthorship W2743124734A5046779846 @default.
• W2743124734 hasAuthorship W2743124734A5047612641 @default.
• W2743124734 hasAuthorship W2743124734A5051913748 @default.
• W2743124734 hasAuthorship W2743124734A5063331477 @default.
• W2743124734 hasBestOaLocation W27431247341 @default.
• W2743124734 hasConcept C126322002 @default.
• W2743124734 hasConcept C126894567 @default.
• W2743124734 hasConcept C2779660313 @default.
• W2743124734 hasConcept C2779918671 @default.
• W2743124734 hasConcept C2781117629 @default.
• W2743124734 hasConcept C71924100 @default.
• W2743124734 hasConceptScore W2743124734C126322002 @default.
• W2743124734 hasConceptScore W2743124734C126894567 @default.
• W2743124734 hasConceptScore W2743124734C2779660313 @default.
• W2743124734 hasConceptScore W2743124734C2779918671 @default.
• W2743124734 hasConceptScore W2743124734C2781117629 @default.
• W2743124734 hasConceptScore W2743124734C71924100 @default.
• W2743124734 hasIssue "8" @default.
• W2743124734 hasLocation W27431247341 @default.
• W2743124734 hasOpenAccess W2743124734 @default.
• W2743124734 hasPrimaryLocation W27431247341 @default.
• W2743124734 hasRelatedWork W2020344899 @default.
• W2743124734 hasRelatedWork W2033363128 @default.
• W2743124734 hasRelatedWork W2038101806 @default.
• W2743124734 hasRelatedWork W2043010698 @default.
• W2743124734 hasRelatedWork W2052947184 @default.
• W2743124734 hasRelatedWork W2089540389 @default.
• W2743124734 hasRelatedWork W2308620135 @default.
• W2743124734 hasRelatedWork W2410371126 @default.
• W2743124734 hasRelatedWork W2460829677 @default.
• W2743124734 hasRelatedWork W2995550955 @default.
• W2743124734 hasVolume "23" @default.
• W2743124734 isParatext "false" @default.
• W2743124734 isRetracted "false" @default.
• W2743124734 magId "2743124734" @default.
• W2743124734 workType "article" @default.